Year
DEALS // DEV.
Country
Therapeutic Area
Study Phase
Deal Type
Product Type
Dosage Form
Lead Product
Target
Lead Product(s) : Undisclosed
Therapeutic Area : Ophthalmology
Study Phase : Preclinical
Recipient : Beckley Psytech
Deal Size : Undisclosed
Deal Type : Acquisition
Negev Labs Announces Licensing and Psychedelic Research Collaborations
Details : The acquisition of Beckley Psytech's Ophthalmology development program aligns with Negev's mission to develop the full therapeutic potential of neuroplastogens.
Product Name : Undisclosed
Product Type : Undisclosed
Upfront Cash : Undisclosed
December 11, 2024
Lead Product(s) : Undisclosed
Therapeutic Area : Ophthalmology
Highest Development Status : Preclinical
Recipient : Beckley Psytech
Deal Size : Undisclosed
Deal Type : Acquisition
Lead Product(s) : Undisclosed
Therapeutic Area : Psychiatry/Psychology
Study Phase : Discovery
Recipient : Alexander Shulgin Research Institute
Deal Size : Undisclosed
Deal Type : Licensing Agreement
Negev Labs Licenses Shulgin Institute, Acquires Beckley Psytech Program
Details : The ASRI licensing agreement provides Negev Labs access to a vast library of drug candidates for the treatment of psychiatric disorder .
Product Name : Undisclosed
Product Type : Undisclosed
Upfront Cash : Undisclosed
December 11, 2024
Lead Product(s) : Undisclosed
Therapeutic Area : Psychiatry/Psychology
Highest Development Status : Discovery
Recipient : Alexander Shulgin Research Institute
Deal Size : Undisclosed
Deal Type : Licensing Agreement
Lead Product(s) : Undisclosed
Therapeutic Area : Psychiatry/Psychology
Study Phase : Discovery
Sponsor : Hadassah Brain Labs
Deal Size : Undisclosed
Deal Type : Collaboration
Negev Labs Announces Licensing and Psychedelic Research Collaborations
Details : Negev Labs and Hadassah Brain Labs collaborate to advance non-hallucinogenic neuroplastogens, redefining safe and accessible psychedelic-inspired therapies for psychiatric and neurological disorders.
Product Name : Undisclosed
Product Type : Undisclosed
Upfront Cash : Undisclosed
December 11, 2024
Lead Product(s) : Undisclosed
Therapeutic Area : Psychiatry/Psychology
Highest Development Status : Discovery
Sponsor : Hadassah Brain Labs
Deal Size : Undisclosed
Deal Type : Collaboration